Mereo BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- Mereo BioPharma's estimated annual revenue is currently $8.1M per year.
- Mereo BioPharma's estimated revenue per employee is $155,000
Employee Data
- Mereo BioPharma has 52 Employees.
- Mereo BioPharma grew their employee count by 4% last year.
Mereo BioPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Clinical Development | Reveal Email/Phone |
2 | VP, Lead Clinical Development | Reveal Email/Phone |
3 | VP, Associate General Counsel & Company Secretary | Reveal Email/Phone |
4 | SVP, Translational Research & Development | Reveal Email/Phone |
5 | VP Head Regulatory Affairs | Reveal Email/Phone |
6 | VP Head Legal | Reveal Email/Phone |
7 | Head Patient Access | Reveal Email/Phone |
8 | Senior Director, Head Clinical Development/Operations | Reveal Email/Phone |
9 | Chief Financial Officer | Reveal Email/Phone |
10 | Director, Clinical Science | Reveal Email/Phone |
Mereo BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is Mereo BioPharma?
Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
keywords:N/A
N/A
Total Funding
52
Number of Employees
$8.1M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mereo BioPharma News
A downtrend has been apparent in MEREO BIOPHARMA (MREO) lately with too much selling pressure. The stock has declined 38.7% over the past...
Published: Apr 21, 2022 By Jazmine Colatriano, M.S.. XRay/GettyStock. Ultragenyx Pharmaceutical and Mereo BioPharma celebrated their first patient dosed in...
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics that aim to improve outcomes for oncology...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.4M | 52 | 2% | N/A |
#2 | $15.1M | 52 | 6% | N/A |
#3 | $5.6M | 52 | 27% | N/A |
#4 | $10.6M | 52 | 37% | N/A |
#5 | $6.6M | 52 | 13% | $2M |